Retractable Technologies (NYSE:RVP – Get Free Report) and Boston Scientific (NYSE:BSX – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.
Profitability
This table compares Retractable Technologies and Boston Scientific’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Retractable Technologies | -41.11% | -17.15% | -9.33% |
| Boston Scientific | 11.26% | 17.23% | 9.52% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Retractable Technologies and Boston Scientific, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Retractable Technologies | 0 | 0 | 0 | 0 | 0.00 |
| Boston Scientific | 0 | 1 | 21 | 1 | 3.00 |
Risk & Volatility
Retractable Technologies has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.
Earnings & Valuation
This table compares Retractable Technologies and Boston Scientific”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Retractable Technologies | $43.60 million | 0.54 | -$7.01 million | ($0.54) | -1.46 |
| Boston Scientific | $15.91 billion | 9.73 | $1.59 billion | $1.25 | 84.00 |
Boston Scientific has higher revenue and earnings than Retractable Technologies. Retractable Technologies is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 54.6% of Retractable Technologies shares are owned by insiders. Comparatively, 0.5% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Boston Scientific beats Retractable Technologies on 13 of the 15 factors compared between the two stocks.
About Retractable Technologies
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Receive News & Ratings for Retractable Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retractable Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
